MA28330A1 - Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine - Google Patents
Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrineInfo
- Publication number
- MA28330A1 MA28330A1 MA29074A MA29074A MA28330A1 MA 28330 A1 MA28330 A1 MA 28330A1 MA 29074 A MA29074 A MA 29074A MA 29074 A MA29074 A MA 29074A MA 28330 A1 MA28330 A1 MA 28330A1
- Authority
- MA
- Morocco
- Prior art keywords
- morpholine derivatives
- norepinephrine
- recapture inhibitors
- inhibitors
- norepinephrine recapture
- Prior art date
Links
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 title 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229960002748 norepinephrine Drugs 0.000 title 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
« DERIVES DE MORPHOLINE EN TANT QU'INHIBITEURS DE LA RECAPTAGE DE LA NOREPINEPHRINE » La présente invention concerne des composés représentés par la formule générale (I), qui sont des inhibiteurs du recaptage de la norépinéphrine. De ce fait, ils peuvent convenir pour le traitement de troubles du système nerveux central et/ou périphérique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0326148.4A GB0326148D0 (en) | 2003-11-10 | 2003-11-10 | Morpholine derivatives |
| US53545904P | 2004-01-09 | 2004-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28330A1 true MA28330A1 (fr) | 2006-12-01 |
Family
ID=29726235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29074A MA28330A1 (fr) | 2003-11-10 | 2006-06-02 | Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7423037B2 (fr) |
| EP (2) | EP2223916A1 (fr) |
| JP (1) | JP4850068B2 (fr) |
| KR (1) | KR100783855B1 (fr) |
| CN (1) | CN1878762B (fr) |
| AR (1) | AR046927A1 (fr) |
| AT (1) | ATE478057T1 (fr) |
| AU (1) | AU2004289616B2 (fr) |
| BR (1) | BRPI0415273B8 (fr) |
| CA (1) | CA2544649C (fr) |
| CR (1) | CR8390A (fr) |
| CY (1) | CY1110796T1 (fr) |
| DE (1) | DE602004028750D1 (fr) |
| DK (1) | DK1682523T3 (fr) |
| EA (1) | EA009960B1 (fr) |
| EC (1) | ECSP066555A (fr) |
| ES (1) | ES2348872T3 (fr) |
| GB (1) | GB0326148D0 (fr) |
| HR (1) | HRP20100476T1 (fr) |
| IL (1) | IL175365A (fr) |
| MA (1) | MA28330A1 (fr) |
| MY (1) | MY141048A (fr) |
| NO (1) | NO336268B1 (fr) |
| NZ (1) | NZ546067A (fr) |
| PE (1) | PE20050491A1 (fr) |
| PL (1) | PL1682523T3 (fr) |
| PT (1) | PT1682523E (fr) |
| SI (1) | SI1682523T1 (fr) |
| SV (1) | SV2006001934A (fr) |
| TW (1) | TWI339658B (fr) |
| UA (1) | UA85198C2 (fr) |
| WO (1) | WO2005047272A1 (fr) |
| ZA (1) | ZA200603680B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| RU2613633C1 (ru) * | 2016-03-09 | 2017-03-21 | федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) | Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность |
| GB201915753D0 (en) * | 2019-10-30 | 2019-12-11 | Univ Warwick | Alzheimer's disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2645640A (en) | 1953-07-14 | Phenthiazine derivatives | ||
| NL108827C (fr) | 1956-04-09 | |||
| GB895309A (en) | 1959-11-18 | 1962-05-02 | Res Lab Dr C Janssen Nv | Pyrrolidine and piperidine derivatives |
| US3141823A (en) | 1962-09-04 | 1964-07-21 | Res Lab Dr C Janssen N V | Method for producing analgesia |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| GB8908085D0 (en) | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| US5238945A (en) | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| EG23659A (en) | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| WO1999015177A1 (fr) | 1997-09-23 | 1999-04-01 | Eli Lilly And Company | Traitement des troubles lies a l'hyperactivite et au deficit de l'attention |
| BR9907203A (pt) * | 1998-01-21 | 2000-10-17 | Glaxo Group Ltd | "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " |
| WO2001000214A1 (fr) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Composes inhibiteurs de la kinase src |
| ATE305788T1 (de) * | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von inkontinenz |
| GB0120461D0 (en) * | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| JP2004277318A (ja) * | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物 |
| FR2852954B1 (fr) * | 2003-03-28 | 2006-07-14 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
-
2003
- 2003-11-10 GB GBGB0326148.4A patent/GB0326148D0/en not_active Ceased
-
2004
- 2004-10-22 TW TW093132096A patent/TWI339658B/zh not_active IP Right Cessation
- 2004-10-28 EP EP10162865A patent/EP2223916A1/fr not_active Withdrawn
- 2004-10-28 CA CA2544649A patent/CA2544649C/fr not_active Expired - Lifetime
- 2004-10-28 KR KR1020067008999A patent/KR100783855B1/ko not_active Expired - Lifetime
- 2004-10-28 HR HR20100476T patent/HRP20100476T1/hr unknown
- 2004-10-28 EA EA200600945A patent/EA009960B1/ru unknown
- 2004-10-28 DK DK04794209.9T patent/DK1682523T3/da active
- 2004-10-28 JP JP2006539492A patent/JP4850068B2/ja not_active Expired - Lifetime
- 2004-10-28 DE DE602004028750T patent/DE602004028750D1/de not_active Expired - Lifetime
- 2004-10-28 US US10/577,841 patent/US7423037B2/en not_active Expired - Lifetime
- 2004-10-28 EP EP04794209A patent/EP1682523B1/fr not_active Expired - Lifetime
- 2004-10-28 ES ES04794209T patent/ES2348872T3/es not_active Expired - Lifetime
- 2004-10-28 PL PL04794209T patent/PL1682523T3/pl unknown
- 2004-10-28 SI SI200431540T patent/SI1682523T1/sl unknown
- 2004-10-28 WO PCT/US2004/032771 patent/WO2005047272A1/fr not_active Ceased
- 2004-10-28 AT AT04794209T patent/ATE478057T1/de active
- 2004-10-28 PT PT04794209T patent/PT1682523E/pt unknown
- 2004-10-28 BR BRPI0415273A patent/BRPI0415273B8/pt not_active IP Right Cessation
- 2004-10-28 NZ NZ546067A patent/NZ546067A/en not_active IP Right Cessation
- 2004-10-28 AU AU2004289616A patent/AU2004289616B2/en not_active Expired
- 2004-10-28 CN CN2004800331155A patent/CN1878762B/zh not_active Expired - Lifetime
- 2004-10-28 UA UAA200604519A patent/UA85198C2/ru unknown
- 2004-11-08 MY MYPI20044640A patent/MY141048A/en unknown
- 2004-11-09 AR ARP040104126A patent/AR046927A1/es active IP Right Grant
- 2004-11-09 PE PE2004001093A patent/PE20050491A1/es active IP Right Grant
- 2004-11-10 SV SV2004001934A patent/SV2006001934A/es unknown
-
2006
- 2006-05-01 IL IL175365A patent/IL175365A/en active IP Right Grant
- 2006-05-09 EC EC2006006555A patent/ECSP066555A/es unknown
- 2006-05-09 ZA ZA200603680A patent/ZA200603680B/en unknown
- 2006-05-10 CR CR8390A patent/CR8390A/es unknown
- 2006-06-02 MA MA29074A patent/MA28330A1/fr unknown
- 2006-06-12 NO NO20062700A patent/NO336268B1/no unknown
-
2010
- 2010-09-23 CY CY20101100858T patent/CY1110796T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30988B1 (fr) | Composes destines a inhiber la progression mitotique | |
| TNSN06300A1 (fr) | Derives d'imidazole pour le traitement de troubles neurodegeneratifs | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
| MA35836B1 (fr) | 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1 | |
| EA200601798A1 (ru) | Замещенные соединения морфолина для лечения расстройств центральной нервной системы | |
| TNSN05249A1 (fr) | Benzopyrannes utiles pour le traitement d'etats inflammatoires | |
| MA28077A1 (fr) | Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes | |
| DK1480961T3 (da) | Glutaminylbaserede DPIV-inhibitorer | |
| BR0313265A (pt) | Compostos e respectivos processos de preparação, uso e formulações farmacêuticas e métodos de prevenção e/ou tratamento de distúrbios mediados por receptor mglur5 e de inbição da ativação de receptores mglu r5. | |
| MA30412B1 (fr) | Composés Pharmaceutiques | |
| MA32655B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| MA33242B1 (fr) | Composes pour le traitement de troubles metaboliques | |
| ATE356621T1 (de) | (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum | |
| MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| DK1456380T3 (da) | SMAD7-inhibitorer til behandling af CNS-sygdomme | |
| MA27676A1 (fr) | 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| MA32506B1 (fr) | Nouveaux composes |